首页|卵巢正常反应人群拮抗剂方案单用高纯度尿促性素促排卵的临床效果

卵巢正常反应人群拮抗剂方案单用高纯度尿促性素促排卵的临床效果

扫码查看
目的 比较卵巢正常反应人群(NOR)拮抗剂方案中单用高纯度尿促性素(HP-hMG)与重组人卵泡刺激素(rF-SH)促排卵的临床结局。方法 回顾性收集行NOR拮抗剂助孕的患者,根据拮抗剂方案中采用超促排卵药物的不同,分为HP-hMG组和rFSH组。统计两组患者基本信息、促排卵情况、实验室指标以及临床结局等指标。结果 最终纳入614 例 NOR 患者:HP-hMG 组(n=216),rFSH 组(n=398)。两组间hCG注射日P及LH水平差异无统计学意义,HP-hMG组hCG注射日E2水平显著降低(P<0。001);HP-hMG组生化妊娠率(69。23%vs 63。51%)以及临床妊娠率(66。67%vs 59。46%)较rFSH组有升高的趋势。HP-hMG组卵巢过度刺激综合征(OHSS)发生率(2。31%vs 3。02%)较rFSH组有降低趋势。结论 对于NOR接受拮抗剂方案助孕的患者,与采用rFSH相比,单独使用HP-hMG能够获得同样较好的临床妊娠率,并在降低OHSS发生率方面具有一定优势。
Effect of highly purified hMG on ovulation induction in normal ovarian responder patients with antagonist protocol
Objective To compare the differences in clinical outcomes of ovulation induction with highly purified human menopausal gonadotropin(HP-hMG,Menopur)versus recombinant human follicle stimulating hormone(rFSH,Gonal-F)in normal ovarian responder patients treated with the GnRH-antagonist protocol.Methods Pa-tients treated with the GnRH-antagonist protocol were retrospectively analyzed and divided by gonadotropin(Gn)usage into HP-hMG group and rFSH group.The basic characteristics,ovulation induction method,laboratory inde-xes,and clinical outcomes were compared between the two groups.Results A total of 614 normal ovarian re-sponder patients were enrolled in the study,with 216 in the HP-hMG group and 398 in the rFSH group.There was no significant difference in P levels and LH levels on the hCG trigger day between the two groups.However,the E2 levels on the hCG trigger day were significantly lower in the HP-hMG group(P<0.001).Moreover,the HP-hMG group had a higher biochemical pregnancy rate(69.23%vs 63.51%)and clinical pregnancy rate(66.67%vs 59.46%)compared to the rFSH group.The incidence of OHSS in the HP-hMG group(2.31%vs 3.02%)showed a decreasing trend compared to the rFSH group.Conclusion Compared to rFSH,HP-hMG offers distinct advanta-ges in reducing the incidence of OHSS and improving pregnancy outcomes in normal ovarian responder patients un-dergoing pituitary suppression with the GnRH-antagonist protocol.

normal ovarian responderHP-hMGrFSHin vitro fertilization-embryo transfercontrolled ovulation induction

徐千花、曹云霞、曾娟

展开 >

安徽医科大学第一附属医院妇产科,合肥 230032

国家卫生健康委配子及生殖道异常研究重点实验室,合肥 230032

出生人口健康教育部重点实验室,合肥 230032

生殖健康与遗传安徽省重点实验室,合肥 230032

安徽省生命资源保存与人工器官工程技术研究中心,合肥 230032

展开 >

卵巢正常反应人群 高纯度尿促性素 重组人卵泡刺激素 体外受精-胚胎移植 控制性超促排卵

国家自然科学基金生殖健康与遗传安徽省重点实验室开放课题基金

82301864RHG-2021-1

2024

安徽医科大学学报
安徽医科大学

安徽医科大学学报

CSTPCD北大核心
影响因子:1.095
ISSN:1000-1492
年,卷(期):2024.59(6)
  • 15